A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus

Inclusion Criteria

• Are males or females, diagnosed with Type 2 Diabetes Mellitus for greater than or equal to 3 months prior to screening.
• Male patients agree to use a reliable method of birth control during the study and for 3 months following the last dose of study drug. Female patients must be of non-child-bearing potential due to surgical sterilization or menopause.
• Have a body mass index (BMI) between 18.5 and 40.0 kilogram/square meter (kg/m²), inclusive.
• Have Type 2 Diabetes Mellitus controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (e.g. metformin) prior to screening, and have been taking a stable dose for >7 days prior to the first dosing occasion.
• Have a fasting blood glucose value at screening >126 milligram/deciliter (mg/dL) (7.0 [millimoles/liter] mmol/L) for patients on a controlled diet, and >108 mg/dL (6.0 mmol/L) for patients on oral antidiabetic medication, with an upper limit of 180 mg/dL (approximately 9.9 mmol/L) in each case.
• Have a hemoglobin A1c (HbA1c) (indicates what your average blood glucose level has been in the past 3 months) value at screening (or within 4 weeks prior to screening) of 6.5% to 9.5%. If HbA1c is between 6.1% and 6.5%, patients may participate in the study providing they are receiving permissible oral antidiabetic medication.
• Have clinical laboratory test results within normal ranges as determined by the study doctor.
• Can provide enough blood in order to undergo the blood sampling required for the study.
• Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
• Have signed the consent form approved by Lilly and the Ethical Review Board (ERB) governing the site.

Exclusion Criteria

• Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
• Have previously been exposed to, or have known allergies to glucagon-like-peptide-1 (GLP-1)-related compounds including LY2189265.
• Are persons who have previously completed or withdrawn from this study or any other study investigating LY2189265 or have received glucagon-like peptides or incretin mimetics in the past 3 months.
• Have taken certain Type 2 Diabetes medications within 30 days prior to screening.
• Have an abnormality in the electrocardiogram (ECG) performed at screening.
• Have poorly controlled high blood pressure (systolic blood pressure >160 millimeters of mercury [mmHg] and/or diastolic blood pressure >100 mmHg).
• Have a history or presence of respiratory, liver, kidney, hormonal, blood, or neurological disorders which may put the patient at risk when taking the study medication; or may interfere with the interpretation of data.
• Have a history or presence of cardiovascular disorder within the last year, or signs of congestive heart failure, or are expected to require coronary artery bypass surgery or angioplasty.
• Have a history or presence of pancreatitis or certain gastrointestinal disorders.
• Have been exposed to radiation from clinical trials and from diagnostic X-ray or are exposed routinely via your job worker.
• Have any non-removable metal objects such as metal plates, screws etc. in their chest or abdominal area.
• Have had acute diarrhea or constipation within 14 days of study screening.
• Show evidence of significant active neuropsychiatric disease.
• Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.
• Intend to start new medication during the study, including over-the-counter and herbal medication.
• Have donated blood of more than 500 milliliter (mL) within the last month prior to screening.
• Have an average weekly alcohol intake that exceeds the study centre's guidelines an